JP2009504788A - 化学療法の強化方法 - Google Patents

化学療法の強化方法 Download PDF

Info

Publication number
JP2009504788A
JP2009504788A JP2008527219A JP2008527219A JP2009504788A JP 2009504788 A JP2009504788 A JP 2009504788A JP 2008527219 A JP2008527219 A JP 2008527219A JP 2008527219 A JP2008527219 A JP 2008527219A JP 2009504788 A JP2009504788 A JP 2009504788A
Authority
JP
Japan
Prior art keywords
group
ring
formula
atom
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008527219A
Other languages
English (en)
Japanese (ja)
Inventor
ガーリー ジェイ ブリッジャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37758501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009504788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2009504788A publication Critical patent/JP2009504788A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008527219A 2005-08-19 2006-08-21 化学療法の強化方法 Pending JP2009504788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70997805P 2005-08-19 2005-08-19
US73473605P 2005-11-08 2005-11-08
PCT/US2006/032668 WO2007022523A2 (en) 2005-08-19 2006-08-21 Methods to enhance chemotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013045053A Division JP2013107903A (ja) 2005-08-19 2013-03-07 化学療法の強化方法

Publications (1)

Publication Number Publication Date
JP2009504788A true JP2009504788A (ja) 2009-02-05

Family

ID=37758501

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008527219A Pending JP2009504788A (ja) 2005-08-19 2006-08-21 化学療法の強化方法
JP2013045053A Pending JP2013107903A (ja) 2005-08-19 2013-03-07 化学療法の強化方法
JP2013169087A Pending JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013045053A Pending JP2013107903A (ja) 2005-08-19 2013-03-07 化学療法の強化方法
JP2013169087A Pending JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Country Status (9)

Country Link
US (1) US20070043012A1 (https=)
EP (1) EP1951046B1 (https=)
JP (3) JP2009504788A (https=)
CN (1) CN101365336B (https=)
AU (1) AU2006280945A1 (https=)
BR (1) BRPI0615180A2 (https=)
CA (1) CA2619828A1 (https=)
IL (1) IL189599A0 (https=)
WO (1) WO2007022523A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508005A (ja) * 2014-02-19 2017-03-23 マイクロコンスタンツ チャイナ インク ケモカイン受容体アンタゴニストおよびその併用療法
JP2018513201A (ja) * 2015-04-25 2018-05-24 ザ ジェネラル ホスピタル コーポレイション 抗ｆｕｇｅｔａｃｔｉｃ剤と抗癌剤の併用療法、および、癌の治療のための組成物
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
JP2022070814A (ja) * 2020-10-27 2022-05-13 行政院原子能委員會核能研究所 複合体、造影剤、及びｃｘｃｒ４関連疾患を治療又は診断するための医薬品

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) * 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
CA2673719C (en) * 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
US20110207814A1 (en) * 2009-12-23 2011-08-25 Pranela Rameshwar Combination Therapy for Breast Cancer Treatment
US20130310442A1 (en) * 2010-09-09 2013-11-21 Noxxon Pharma Ag SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
EP2978439B1 (en) 2013-03-24 2017-08-16 Biokine Therapeutics Ltd. A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
CA2928315C (en) 2013-10-31 2023-03-21 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
KR101759688B1 (ko) * 2015-01-16 2017-07-20 서울대학교산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
WO2016114634A2 (ko) * 2015-01-16 2016-07-21 서울대학교 산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
CN108348545A (zh) * 2015-09-18 2018-07-31 综合医院公司以麻省总医院名义经营 具有抗趋除特性的修饰的t细胞及其用途
CN109069426B (zh) * 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3856225A1 (en) 2018-09-25 2021-08-04 BioLineRx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087068A2 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
JP2004538303A (ja) * 2001-07-31 2004-12-24 アノーメッド インコーポレイティド 前駆／幹細胞を動員する方法
US6872714B1 (en) * 1998-07-08 2005-03-29 Anormed Inc. Methods to modulate conditions mediated by the CXCR4 receptor
JP2005518397A (ja) * 2001-12-21 2005-06-23 アノーメド インコーポレイテッド 高い有効性を有するケモカインレセプタ結合複素環式化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005204A (en) * 1973-03-23 1977-01-25 Burroughs Wellcome Co. Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
BR0010655A (pt) 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
DE60042030D1 (de) 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
PT1317451E (pt) 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6835731B2 (en) 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
EP1361851B1 (en) 2001-01-23 2007-02-21 P & G-Clairol, Inc. Primary intermediates for oxidative coloration of hair
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20040202935A1 (en) 2003-04-08 2004-10-14 Jeremy Barker Cathode active material with increased alkali/metal content and method of making same
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
ATE514434T1 (de) * 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872714B1 (en) * 1998-07-08 2005-03-29 Anormed Inc. Methods to modulate conditions mediated by the CXCR4 receptor
JP2004538303A (ja) * 2001-07-31 2004-12-24 アノーメッド インコーポレイティド 前駆／幹細胞を動員する方法
JP2005518397A (ja) * 2001-12-21 2005-06-23 アノーメド インコーポレイテッド 高い有効性を有するケモカインレセプタ結合複素環式化合物
WO2004087068A2 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 102, no. 11, JPN6012007333, 2003, pages 236, ISSN: 0002326772 *
LEUKEMIA, vol. 17, JPN6012007329, 2003, pages 1294 - 1300, ISSN: 0002147261 *
ZENG,Z. ET AL: "CXCR4 inhibition as a therapeutic strategy in leukemia", BLOOD, vol. 104, no. 11, JPN6012007330, 2004, pages 133, ISSN: 0002147262 *
メルクマニュアル 第１７版 日本語版, JPN6012047508, 1999, pages 944 - 947, ISSN: 0002326771 *
最新 医学大辞典, JPN6012007332, 2001, pages 235, ISSN: 0002147263 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508005A (ja) * 2014-02-19 2017-03-23 マイクロコンスタンツ チャイナ インク ケモカイン受容体アンタゴニストおよびその併用療法
JP2018513201A (ja) * 2015-04-25 2018-05-24 ザ ジェネラル ホスピタル コーポレイション 抗ｆｕｇｅｔａｃｔｉｃ剤と抗癌剤の併用療法、および、癌の治療のための組成物
US11305017B2 (en) 2015-04-25 2022-04-19 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
JP2022070814A (ja) * 2020-10-27 2022-05-13 行政院原子能委員會核能研究所 複合体、造影剤、及びｃｘｃｒ４関連疾患を治療又は診断するための医薬品
JP7239662B2 (ja) 2020-10-27 2023-03-14 行政院原子能委員會核能研究所 複合体、造影剤、及びｃｘｃｒ４関連疾患を治療又は診断するための医薬品

Also Published As

Publication number Publication date
WO2007022523A3 (en) 2007-11-22
IL189599A0 (en) 2008-08-07
EP1951046B1 (en) 2012-07-18
BRPI0615180A2 (pt) 2011-05-03
US20070043012A1 (en) 2007-02-22
CA2619828A1 (en) 2007-02-22
JP2013231086A (ja) 2013-11-14
CN101365336B (zh) 2013-05-29
AU2006280945A1 (en) 2007-02-22
WO2007022523A2 (en) 2007-02-22
CN101365336A (zh) 2009-02-11
EP1951046A4 (en) 2010-03-17
JP2013107903A (ja) 2013-06-06
EP1951046A2 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
JP2013231086A (ja) 化学療法の強化方法
TWI732353B (zh) 藥物組成物及其用途
EP3277276B1 (en) Methods of administering glutaminase inhibitors
BRPI0715393A2 (pt) terapia de combinaÇço
CN101495115A (zh) 组合治疗
JP2008509928A (ja) 前駆／幹細胞を動員するためのケモカインの組み合わせ
KR20100080516A (ko) 아레나바이러스 감염을 치료하기 위한 항바이러스 약물
US10639304B2 (en) Kinase inhibitors
JP2017523178A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
KR20150096445A (ko) 뮤신 관련 질환의 치료
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
JP2012516353A (ja) 血液系悪性腫瘍を治療するための方法及び組成物
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
JP2023509191A (ja) 癌を治療するための組み合わせ療法
ES2317913T3 (es) Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.
MX2008002374A (en) Methods to enhancechemotherapy
JP2016525118A (ja) がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423